Gariot P, Barrat E, Drouin P, Genton P, Pointel J P, Foliguet B, Kolopp M, Debry G
Metabolism. 1987 Mar;36(3):203-10. doi: 10.1016/0026-0495(87)90177-6.
We have studied liver biopsies obtained in 12 hyperlipoproteinemic (HLP) patients (type II, 6; type IV, 6) treated with diet and fenofibrate, and in 15 patients (type II, 11; type IV, 4) receiving diet only. Electron microscopy of liver biopsies and the morphometric analysis according to the method of Weibel and Rohr showed mitrochondrial changes in patients treated with fenofibrate, these changes depending on the type of hyperlipoproteinemia. In type II HLP, we found a decreased volume of normal mitochondria (fenofibrate, 125.72 +/- 17.04 X 10(-3) cm3/cm3; diet only, 185.84 +/- 8.96 10(-3), P less than .05). In type IV HLP we found a decreased number of giant mitochondria (fenofibrate, 0.08 +/- 0.03 X 10(10) cm-3; diet only, 0.32 +/- 0.08 X 10(10) cm-3, P less than .05) and a decreased volume of altered mitochondria (fenofibrate, 6.00 +/- 1.44 X 10(-3) cm3/cm3; diet only, 13.61 +/- 1.17 X 10(-3), P less than .05). In contrast with the rodent studies, the present study shows no change in the number of volume of peroxisomes.
我们研究了12例接受饮食和非诺贝特治疗的高脂蛋白血症（HLP）患者（II型6例，IV型6例）以及15例仅接受饮食治疗的患者（II型11例，IV型4例）的肝脏活检样本。肝脏活检样本的电子显微镜检查以及根据韦贝尔和罗尔方法进行的形态计量分析显示，接受非诺贝特治疗的患者线粒体有变化，这些变化取决于高脂蛋白血症的类型。在II型HLP患者中，我们发现正常线粒体体积减小（非诺贝特治疗组，125.72±17.04×10⁻³ cm³/cm³；仅饮食治疗组，185.84±8.96×10⁻³，P＜0.05）。在IV型HLP患者中，我们发现巨型线粒体数量减少（非诺贝特治疗组，0.08±0.03×10¹⁰ cm⁻³；仅饮食治疗组，0.32±0.08×10¹⁰ cm⁻³，P＜0.05）以及异常线粒体体积减小（非诺贝特治疗组，6.00±1.44×10⁻³ cm³/cm³；仅饮食治疗组，13.61±1.17×10⁻³，P＜0.05）。与啮齿动物研究不同，本研究显示过氧化物酶体的数量或体积没有变化。
